Attendee search 

Nenupharma was born out of a shared passion to contribute to the development of innovative pharmaceuticals in different disease areas.

Nenupharma uses the best of skills that have been developed through an extensive career in pharmaceutical industry, regulatory affairs, market access, medical practice and life science.

Nenupharma has been working with high level experts on different levels and enjoys reliable, professional and ethical reputation among its network as well as its customers.

For more information, visit our website at:
www.nenupharma.com

ZY Therapeutics Inc. is a venture backed startup company focusing on developing innovative precision drug delivery technology. It was founded by two scientists in 2015 in North Carolina. In 2017, ZY’s leading project won collaboration award from Nanotechnology Characterization Lab (NCL), part of national lab established by FDA, NCI and NIST in a concerted effort to regulate and support nanotechnology in oncology space. ZY’s proprietary delivery platforms currently focus on optimized injectable formulations to deliver oncology therapy to the action sites. The first biodegradable oncology nano-formulation, ZY-010-PNP, completed Pre-IND discussion with the FDA and agreement on 505b(2) regulatory pathway was achieved. Further, the isotope labeling human plasma In vitro study as well as canine pharmacokinetic study conducted by NCL suggest a unique drug releasing profile in comparison to the benchmark brands suggesting enhanced the therapeutic effect with lower safety concern. The active targeting delivery nanomedicine ZY-012-CNP for prostate cancer is in preclinic development and scheduled to file Pre-IND application in 2021. Additional products are in encapsulation feasibility studies including targeting dry eye disease and other solid tumors. The target indications cover majority of solid tumors, including but not limited to TNBC, Ovarian Cancer and mCPRC, of which xenograft in vivo models have proved the drug efficacy.
ZY has developed multiple platform technologies and related patents were filed to protect global rights. The key platform patent was awarded by USPTO in 2019. Additional patents on individual product will be filed to protect the exclusive rights. This layered IP strategy ensures a long patent life for future product.
Located in Research Triangle Park in North Carolina, ZY Therapeutics has an interdisciplinary R&D team and 4,500+ sf lab space right in the heart of the southeast bio-hub. Co-founder and CEO Dr. Jian Bao has 18 years’ experience in pharmaceutical development, from discovery to clinical development. She received PhD from University of Pittsburgh and B.S. from Beijing University, both in Chemistry. The core team has a combined decades of pharmaceutical product development experience, with veteran cross-functional team leaders. ZY has assembled an advisor board that consists of world class experts in drug delivery and oncologists from both academia and industry.
ZY Therapeutics is actively seeking funding and collaboration to further develop our platform technologies and promising candidates. We look forward to taking our nano-formulations to clinic in 2021 and beyond.

Bioxis, creates biomaterial scaffolds that help regenerate tissues, improve patient outcomes, and provide better healthcare opportunities for doctors. We are focused on developing medical devices based on patented biomaterials technology with potentially accelerated pathways to the aesthetic dermatology market.

Our lead medical device candidate MTI-12 is currently at the pre-clinical stage for aesthetic indications; and our hyaluronic acid-based dermal filler brand, CYTOSIAL, has established into exclusive distribution agreements with distributors in Europe and Asia.

Neuro-Zone, since 13 years, supports drug discovery, drug repurposing and research projects in the fields of inflammation and age-related pathologies.
In particular, we have developed pathology-specific platforms to generate rapid and informative data on efficacy, toxicity, metabolism and mechanism of action, supported by proprietary technologies such as MicroTISSUE (dissecting microenvironment-cell interaction in complex inflammatory scenarios) or MITOS (a comprehensive analytical platform for quantitative analysis of mitochondrial function ).
Our approach enables effective selection and ranking of the most promising candidates per indication.
Moreover, we profile candidates at different level of complexity starting from:
a) pharmacology profiling (GPCR; Ion Channel receptors)
b) identification of biochemical pathways responsible for therapeutic efficacy (transcriptomics)
c) disease modified barrier permeability (BBB and endothelial)

A human-genetics driven next generation immunity-oncology company

We are a European oncology start-up developing an entirely novel platform of small molecule drugs to cure currently untreatable cancers.We wholly own a pipeline of molecules that are active via novel mechanisms in cancer and several other therapeutic areas.
The mechanism of action of our lead drug, Ag5, targets cancer cells generating high levels of Reactive Oxygen Species (ROS). High ROS tumours are, in general, untreatable. This group of cancers includes KRAS-mutation driven cancers, which comprise around 30% of all cancer cases, and the worst prognosis group. There is currently no treatment for KRAS mutant cancers, which lead to more than 1 million deaths worldwide every year.
Glioblastoma Multiforme (GBM), the commonest primary brain cancer, is also a high-ROS cancer, despite the absence of mutated KRAS. There have been no new treatment options in GBM for 20 years, and prognosis is poor-averaging 18 months.
We have a follow-on compound and a pipeline of innovative molecules addressing both cancer and non-cancerous conditions.
We are raising a series A round which will allow us to gain clinical proof of concept.

   Glenpharma AB is a small privately owned research spin-off from Pfizer-Pharmacia, formed in Sweden in 2002 to exploit novel technology patented by its founders. 

We offer patented synergistic combinations of biopolymers for 

a) accelerated repair of acute tendon /ligament injuries in human applications ( such as sprained ligaments / tendons in shoulder, elbow, knee, ankle, etc , in both sports injury scenarios and in the elderly ) , or in veterinary indications (e.g. high performance horses) .  The product accelerates healing at least 3 times faster than the normal healing process. 

b) for prevention of unwanted adhesions between tissues after major thoracic, abdominal , fertility or orthopedic surgery. In studies on prevention of difficult adhesions after cardiac surgery, for example, adhesion scores were < 10% of those in control groups.

c) for effective control of acute pain in advanced joint disease (osteo-arthritis (OA)  .  Clinical documentation in advanced OA indicates that onset of pain relief is much faster and of longer duration than current standards for viscosupplementation. 

Each of the above biopolymer "viscous fluid implants" are also ideal drug delivery media for treatment of ancillary complications.

All component biopolymers are well documented APIs, i.e. without the toxicty and other regulatory issues generally associated with "New Chemical Entities".  Glenpharma´s current patent protection covers most major international markets including USA, Europe and P R China.

Glenpharma is primarily seeking Chinese partners for out-licensing within the fields of orthopedics or major surgery.. If neccessary , we can offer contract-manufacturing options in Europe if not available in China. 

Contract regulatory and clinical research services, U.S. HQ with satellite offices in Taiwan and Europe.
FDA, EMA, etc. worldwide regulatory approval services for drugs, devices, and diagnostics.
Worldwide clinical testing for safety and efficacy

Aequor discovered a new genus and several new species of marine microbes that produce “green,” non-toxic chemicals that target Gram-negative and Gram-positive bacteria and fungi, and uniquely remove biofilm in minutes and prevent biofilm formation for long periods of time. They kill the antimicrobial resistant (AMR) bacteria and fungi alone and as "potentiators" of very low doses (sub-MIC) of otherwise ineffective antibiotics, including Penicillin, to kill the AMR "Superbug" pathogens.
Biofilm is the first resistance response of microorganisms to protect themselves against environmental stresses and is associated with most infections and diseases. Removal of biofilm by surface scraping, UV, heat, biocides and antibiotics, etc. signal to the underlying microorganisms when and how fast to build a thicker biofilm shield.
The U.S. Centers for Disease Control (CDC) associate biofilm with 90% of hospital-acquired infections, such as those caused by contamination on indwelling medical devices, ventilators, and water and air systems. The CDC recently reported that 20% of U.S. COVID deaths were due to these secondary infections. Additional life-threatening infections are increasingly traced to biofilm in air and water systems in institutional and commercial buildings and homes. For example, Legionnaire’s Disease, which claimed 17 lives, was traced to biofilm in a hotel’s air conditioners that became aerosolized and inhaled. It is no coincidence that every pathogen on the CDC and WHO lists of urgent threats, pandemic threats, and bioterrorist threats is a biofilm-former. Every drug-resistant “Superbug” strain is a biofilm-former and is considered incurable. Additionally, several microbial species are captures in the same biofilm, increasing the incidence of horizontal gene transfer (Li et al., 2001; Angles et al., 1993; Dunny et al., 1995) and spawning the emergence of new antimicrobial-resistant (AMR) strains.
There are few remedies for biofilm. Physical removal (sterilization, scraping, UV) works for a short-term (e.g., biofilm was recorded on a titanium plate within 30 seconds of sterilization). Biocides (antiseptics, disinfectants, antimicrobials, and antibiotics) are designed to kill free-floating (planktonic), actively growing microorganisms, and the dose of needed to disrupt a biofilm is approximately 1000x the concentrations that are effective against planktonic bacteria (Raffa et al., 2003), which is a dose that is lethal to humans. The overuse of biocides and antibiotics has contributed to the emergence of the AMR Superbugs – and left a cumulative and persistent environmental footprint. Natural antimicrobials, such as silver and other metals, are expensive and eventually trigger the formation of thicker biofilm, resulting in the loss of efficacy over time.